Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain
Phuong T. Nguyen, Hai M. Nguyen, Karen Wagner, Robert G. Stewart, Vikrant Singh, Parashar Thapa, Yi‐Je Chen, Mark Lillya, Anh Tuan Ton, Richard Kondo, Andre Ghetti, Michael W. Pennington, Bruce D. Hammock, Theanne N. Griffith, Jon T. Sack, Heike Wulff, Vladimir Yarov‐Yarovoy
Abstract
The voltage-gated sodium Na V 1.7 channel plays a key role as a mediator of action potential propagation in C-fiber nociceptors and is an established molecular target for pain therapy. ProTx-II is a potent and moderately selective peptide toxin from tarantula venom that inhibits human Na V 1.7 activation. Here we used available structural and experimental data to guide Rosetta design of potent and selective ProTx-II-based peptide inhibitors of human Na V 1.7 channels. Functional testing of designed peptides using electrophysiology identified the PTx2-3127 and PTx2-3258 peptides with IC 50 s of 7 nM and 4 nM for hNa V 1.7 and more than 1000-fold selectivity over human Na V 1.1, Na V 1.3, Na V 1.4, Na V 1.5, Na V 1.8, and Na V 1.9 channels. PTx2-3127 inhibits Na V 1.7 currents in mouse and human sensory neurons and shows efficacy in rat models of chronic and thermal pain when administered intrathecally. Rationally designed peptide inhibitors of human Na V 1.7 channels have transformative potential to define a new class of biologics to treat pain.